AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05328063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles
Study NCT04392284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Counseling
Description: Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin.
Study NCT04392284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin.
Study NCT04858399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation
Description: To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
Study NCT05328063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group.
Study NCT06057831 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Neo-adjuvant Therapy
Description: * TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~* Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~* Chemotherapy regimen for Concurrent CRT: Capecitabine~* Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~* The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist
Study NCT06057831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18FDG-PET/MRI scan
Description: 18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
Study NCT00951444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Given IV
Study NCT00951444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00951444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00951444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04799652 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
Study NCT00951444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04873115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sialanar placebo
Study NCT04873115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sialanar
Description: Sialanar - a licensed glycopyrronium bromide product
Study NCT05240131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
Study NCT05240131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally twice a day.
Study NCT05240131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
Study NCT04873115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Rehabilitation
Description: Standard oral rehabilitation for provided drooling
Study NCT04873115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Rehabilitation
Description: Standard oral rehabilitation for provided drooling
Study NCT05233124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG
Description: Rivaroxaban 15mg
Study NCT05879198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Intervention
Description: The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
Study NCT05233124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid 100mg
Description: Acetylsalicylic acid 100mg
Study NCT05233124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Clopidogrel 75mg
Study NCT05233124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Clopidogrel 75mg
Study NCT05432310 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
Description: Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
Study NCT04415554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography exam of the infant
Study NCT05687370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified dynamic needle tip positioning under ultrasound-guidance
Description: The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
Study NCT05687370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis technique
Description: The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
Study NCT06361433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUFF-01
Description: autologous MSC combined with scaffold
Study NCT06558292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group
Description: Students will experience the operating room environment with virtual reality glasses before clinical practice.
Study NCT05267886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine administered according to its clinical dose stage for cardiogenic shock
Study NCT05267886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Milrinone administered according to its clinical dose stage for cardiogenic shock
Study NCT05267886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline running at a standardized rate
Study NCT05046899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOpH+ Psoriasis Medical Bath
Description: 20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
Study NCT05046899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil Moisturizing Lotion
Description: Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
Study NCT04804046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
Study NCT05243394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified virtual reality treadmill gait training with tDCS
Description: Progressive treadmill gait training in a gamified virtual reality environment with tDCS
Study NCT05243394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified virtual reality treadmill gait training
Description: Progressive treadmill gait training in a gamified virtual reality environment
Study NCT05243394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: Progressive treadmill gait training
Study NCT06179030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum samples
Description: The serum samples were taken from the patients at the 3rd month (switch point)
Study NCT06179030 — intervention group
Intervention type: DRUG
Intervention: dexamethasone implant versus ranibizumab
Description: dexamethasone implant versus ranibizumab will be studied as a secondary outcome
Study NCT06092853 — intervention group
Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) and serum samples
Description: Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
Study NCT04907591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App and wearable device
Description: an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
Study NCT04883658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(2)
Description: QD, PO
Study NCT04887532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 capsule
Description: phase 1 :8mg; phase 2:12mg; phase 3:16mg
Study NCT05691933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block group
Description: Patient will be subjected to bilateral external oblique intercostal plane block
Study NCT05691933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine infusion
Description: Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
Study NCT05730842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506 Tablet
Description: Single Oral Dose - Tablet
Study NCT04883658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study NCT05233982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product
Description: Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
Study NCT05653297 — intervention group
Intervention type: DEVICE
Intervention: Vacuum-Assisted Closure
Description: NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
Study NCT05730842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled EDG-5506 Suspension
Description: Single Oral Dose
Study NCT05730842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled EDG-5506 Intravenous
Description: Single Intravenous Dose
Study NCT05424601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rethink game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
Study NCT05424601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: PsyPills is a mobile app designed to provide personalized psychological pills
Study NCT06427395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 1 mg
Description: Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
Study NCT05042206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-CKD
Description: Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
Study NCT06305208 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic gastric suturing
Description: Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
Study NCT06305208 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic gastric plication
Description: Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
Study NCT06305208 — intervention group
Intervention type: DEVICE
Intervention: Revisional gastroplasty
Description: Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
Study NCT06305208 — intervention group
Intervention type: DEVICE
Intervention: Transoral outlet reduction endoscopy (TORe)
Description: Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
Study NCT04804046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Digestible Maltodextrin
Description: Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
Study NCT06268990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
Study NCT05110807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3617
Description: TQB3617 is a BET inhibitor.
Study NCT05545111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1117568
Description: Active treatment with orally administered NBI-1117568
Study NCT05545111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching NBI-1117568
Study NCT04918160 — intervention group
Intervention type: OTHER
Intervention: Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)
Description: The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
Study NCT04744324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-supporting Care
Description: Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
Study NCT04744324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home health education
Description: Individualized home health education
Study NCT04917718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion from IR Tacrolimus to XR Tacrolimus
Description: All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
Study NCT05015335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: ADA 40mg q2w
Study NCT05015335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX 10mg qw
Study NCT04772391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Sessions
Description: Participant will complete up to 8 exercise sessions
Study NCT05333237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #1: ProvideXtra Drink
Description: Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study NCT06268990 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
Study NCT04968756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective retina therapy SPECTRALIS CENTAURUS device
Description: Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
Study NCT04882553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic echography
Description: Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
Study NCT06305208 — intervention group
Intervention type: DEVICE
Intervention: Duodenal mucosal resurfacing (DMR)
Description: Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
Study NCT06305208 — intervention group
Intervention type: DEVICE
Intervention: Intragastric balloon(s)
Description: The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
Study NCT05333237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #2: Fresubin Energy Drink
Description: Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study NCT05166668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg tablet
Description: letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
Study NCT05420948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.